BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12395372)

  • 1. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma.
    Sun W; Herrera GA
    Hum Pathol; 2002 Oct; 33(10):996-1000. PubMed ID: 12395372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E-cadherin expression in invasive urothelial carcinoma.
    Sun W; Herrera GA
    Ann Diagn Pathol; 2004 Feb; 8(1):17-22. PubMed ID: 15129905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder.
    Sun W; Zhang PL; Herrera GA
    Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):327-31. PubMed ID: 12607601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.
    Izawa JI; Slaton JW; Kedar D; Karashima T; Perrotte P; Czerniak B; Grossman HB; Dinney CP
    Oncol Rep; 2001; 8(1):9-15. PubMed ID: 11115562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E-cadherin cell-adhesion molecule expression as a diagnostic adjunct in urothelial cytology.
    Ross JS; Cheung C; Sheehan C; del Rosario AD; Bui HX; Fisher HA
    Diagn Cytopathol; 1996 Jun; 14(4):310-5. PubMed ID: 8725130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ.
    Bindels EM; Vermey M; van den Beemd R; Dinjens WN; Van Der Kwast TH
    Cancer Res; 2000 Jan; 60(1):177-83. PubMed ID: 10646871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma.
    Amara N; Palapattu GS; Schrage M; Gu Z; Thomas GV; Dorey F; Said J; Reiter RE
    Cancer Res; 2001 Jun; 61(12):4660-5. PubMed ID: 11406532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.
    Messing EM
    Cancer Res; 1990 Apr; 50(8):2530-7. PubMed ID: 1690599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.
    Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR
    Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of transforming growth factor beta1 and its receptors in normal human urothelium and human transitional cell carcinomas.
    Izadifar V; de Boer WI; Muscatelli-Groux B; Maillé P; van der Kwast TH; Chopin DK
    Hum Pathol; 1999 Apr; 30(4):372-7. PubMed ID: 10208456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder.
    Ross JS; del Rosario AD; Figge HL; Sheehan C; Fisher HA; Bui HX
    Hum Pathol; 1995 Sep; 26(9):940-4. PubMed ID: 7672793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of atypical papillary urothelial hyperplasia.
    Swierczynski SL; Epstein JI
    Hum Pathol; 2002 May; 33(5):512-7. PubMed ID: 12094376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model.
    Grippo PJ; Sandgren EP
    Am J Pathol; 2000 Sep; 157(3):805-13. PubMed ID: 10980120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.
    Dyrskjøt L; Kruhøffer M; Thykjaer T; Marcussen N; Jensen JL; Møller K; Ørntoft TF
    Cancer Res; 2004 Jun; 64(11):4040-8. PubMed ID: 15173019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma.
    Lim MG; Adsay NV; Grignon DJ; Osunkoya AO
    Mod Pathol; 2011 Feb; 24(2):241-7. PubMed ID: 20818341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
    Kalantari MR; Ahmadnia H
    Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder].
    Offner FA; Schäfer G; Hittmair A; Ofner D; Grünewald K; Weyrer K; Mattern D; Eberle J; Mikuz G; Feichtinger H
    Verh Dtsch Ges Pathol; 1993; 77():241-6. PubMed ID: 7511289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma.
    Croft PR; Lathrop SL; Feddersen RM; Joste NE
    Arch Pathol Lab Med; 2005 Feb; 129(2):194-9. PubMed ID: 15679420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
    Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
    Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMP3 expression in urothelial carcinomas of the urinary bladder.
    Ozdemir NO; Türk NS; Düzcan E
    Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.